Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$0.28 - $0.75 $3 - $10
-14 Reduced 0.39%
3,591 $1,000
Q2 2023

Aug 14, 2023

SELL
$0.52 - $0.76 $18 - $27
-36 Reduced 0.99%
3,605 $2,000
Q1 2023

May 09, 2023

BUY
$0.56 - $1.15 $787 - $1,618
1,407 Added 62.98%
3,641 $2,000
Q4 2022

Feb 10, 2023

BUY
$0.54 - $21.75 $736 - $29,645
1,363 Added 156.49%
2,234 $1,000
Q3 2022

Nov 10, 2022

SELL
$1.23 - $21.9 $5,622 - $100,104
-4,571 Reduced 83.99%
871 $1,000
Q2 2022

Aug 15, 2022

BUY
$6.1 - $7.15 $12,712 - $14,900
2,084 Added 62.06%
5,442 $6,000
Q1 2022

May 12, 2022

BUY
$5.93 - $7.6 $18,726 - $24,000
3,158 Added 1579.0%
3,358 $10,000
Q4 2021

Feb 14, 2022

BUY
$6.04 - $8.03 $1,208 - $1,605
200 New
200 $1,000
Q3 2021

Nov 15, 2021

SELL
$8.02 - $11.0 $1,868 - $2,563
-233 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$7.59 - $10.48 $2,967 - $4,097
-391 Reduced 62.66%
233 $1,000
Q1 2021

May 17, 2021

BUY
$6.86 - $9.24 $3,724 - $5,017
543 Added 670.37%
624 $4,000
Q4 2020

Feb 16, 2021

BUY
$5.0 - $7.5 $405 - $607
81 New
81 $1,000

About Cyclacel Pharmaceuticals, Inc.


  • Ticker CYCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,539,200
  • Market Cap $7.9M
  • Description
  • Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...
More about CYCC
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.